(Q43259361)

17 November 2017

title

EANM procedure guidelines for brain neurotransmission SPECT/PET using dopamine D2 receptor ligands, version 2. (English)

1 reference

17 November 2017

Zuzana Walker

7

0 references

Flavio Nobili

object named as

Flavio Nobili

5

0 references

Klaus Tatsch

9

object named as

Klaus Tatsch

1 reference

17 November 2017

Koen Van Laere

1

1 reference

17 November 2017

Andrea Varrone

2

1 reference

17 November 2017

Jan Booij

3

1 reference

17 November 2017

Thierry Vander Borght

4

1 reference

17 November 2017

Ozlem L Kapucu

6

1 reference

17 November 2017

Kjell Någren

8

1 reference

17 November 2017

Jacques Darcourt

10

1 reference

17 November 2017

publication date

1 February 2010

1 reference

17 November 2017

number of pages

9

1 reference

European Journal of Nuclear Medicine and Molecular Imaging

inferred from page(s)

published in

1 reference

17 November 2017

volume

37

1 reference

17 November 2017

issue

2

1 reference

17 November 2017

page(s)

434-442

1 reference

https://scigraph.springernature.com/pub.10.1007/s00259-009-1265-z

17 November 2017

exact match

0 references

cites work

Can SPET imaging of dopamine uptake sites replace PET imaging in Parkinson's disease? For.

1 reference

https://api.crossref.org/works/10.1007%2FS00259-009-1265-Z

The role of radiotracer imaging in Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-009-1265-Z

Decrease in human striatal dopamine D2 receptor density with age: a PET study with [11C]raclopride

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-009-1265-Z

[123I]IBZM SPECT for imaging of striatal D2 dopamine receptors in 56 schizophrenic patients taking various neuroleptics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-009-1265-Z

IBZM tool: a fully automated expert system for the evaluation of IBZM SPECT studies.

21 January 2018

1 reference

12 December 2020

SPECT imaging of the dopaminergic system in (premotor) Parkinson's disease

1 reference

12 December 2020

Differentiating multiple system atrophy from Parkinson's disease: contribution of striatal and midbrain MRI volumetry and multi-tracer PET imaging

1 reference

12 December 2020

Complementary PET studies of striatal neuronal function in the differential diagnosis between multiple system atrophy and Parkinson's disease.

1 reference

12 December 2020

Biodistribution and radiation dosimetry of the dopamine D2 ligand 11C-raclopride determined from human whole-body PET.

1 reference

12 December 2020

Optimized, automated striatal uptake analysis applied to SPECT brain scans of Parkinson's disease patients

1 reference

12 December 2020

PET tracers for imaging of the dopaminergic system.

1 reference

12 December 2020

European Association of Nuclear Medicine procedure guidelines for brain neurotransmission SPET using (123)I-labelled dopamine D(2) transporter ligands.

1 reference

12 December 2020

Ethical clinical practice of functional brain imaging. Society of Nuclear Medicine Brain Imaging Council

1 reference

12 December 2020

The basal ganglia matching tools package for striatal uptake semi-quantification: description and validation

1 reference

12 December 2020

Applications of clinical dopamine imaging

1 reference

12 December 2020

Brain receptor imaging

1 reference

12 December 2020

PET study of the pre- and post-synaptic dopaminergic markers for the neurodegenerative process in Huntington's disease

1 reference

12 December 2020

Comparison of striatal dopamine D2 receptors in Parkinson's disease and progressive supranuclear palsy patients using [123I] iodobenzofuran single-photon emission computed tomography.

1 reference

12 December 2020

Dopamine D(2) receptor quantification in extrastriatal brain regions using [(123)I]epidepride with bolus/infusion

1 reference

12 December 2020

Positron emission tomography in acromegaly and other pituitary adenoma patients

1 reference

12 December 2020

Antipsychotic efficacy: relationship to optimal D2-receptor occupancy

1 reference

12 December 2020

Striatal D2-dopamine receptor occupancy during treatment with typical and atypical neuroleptics

1 reference

12 December 2020

Combined 123I-FP-CIT and 123I-IBZM SPECT for the diagnosis of parkinsonian syndromes: study on 72 patients

1 reference

12 December 2020

Fluorinated benzamide neuroleptics--III. Development of (S)-N-[(1-allyl-2-pyrrolidinyl)methyl]-5-(3-[18F]fluoropropyl)-2, 3-dimethoxybenzamide as an improved dopamine D-2 receptor tracer

1 reference

12 December 2020

Imaging of dopamine transporters and D2 receptors in patients with Parkinson's disease and multiple system atrophy

1 reference

12 December 2020

Combination of dopamine transporter and D2 receptor SPECT in the diagnostic evaluation of PD, MSA, and PSP.

1 reference

12 December 2020

Simplified reference tissue model for PET receptor studies.

1 reference

12 December 2020

Diagnostic performance of a 3-D automated quantification method of dopamine D2 receptor SPECT studies in the differential diagnosis of parkinsonism

1 reference

12 December 2020

Dosimetry of iodine-123-epidepride: a dopamine D2 receptor ligand

1 reference

12 December 2020

Dosimetry of iodine-123 iodobenzamide in healthy volunteers

1 reference

12 December 2020

Optimization of automated quantification of 123I-IBZM uptake in the striatum applied to parkinsonism

1 reference

12 December 2020

The dopamine D2 receptor ligand 18F-desmethoxyfallypride: an appropriate fluorinated PET tracer for the differential diagnosis of parkinsonism

1 reference

12 December 2020

Brain radioligands--state of the art and new trends

1 reference

12 December 2020

PET and SPECT functional imaging studies in Parkinsonian syndromes: from the lesion to its consequences

1 reference

12 December 2020

Substituted benzamides as ligands for visualization of dopamine receptor binding in the human brain by positron emission tomography

1 reference

12 December 2020

Iodine-123-epidepride-SPECT: studies in Parkinson's disease, multiple system atrophy and Huntington's disease.

1 reference

12 December 2020

Decrease of D2 receptors indicated by 123I-iodobenzamide single-photon emission computed tomography relates to neurological deficit in treated Wilson's disease

1 reference

12 December 2020

Iodine-123-IBZM dopamine D2 receptor and technetium-99m-HMPAO brain perfusion SPECT in the evaluation of patients with and subjects at risk for Huntington's disease

1 reference

12 December 2020

10.1007/S00259-009-1265-Z

Identifiers

DOI

1 reference

17 November 2017

1 reference